New drug ZG006 takes on chemo in advanced cancer battle
NCT ID NCT07595913
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called ZG006 against standard chemotherapy for people with advanced neuroendocrine carcinoma, a type of cancer. About 240 adults who have already had other treatments will be randomly assigned to receive either ZG006 or a chemotherapy chosen by their doctor. The main goal is to see if ZG006 helps people live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE; CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Two-Drug combo aims to stall rare gut tumors
- Could a PARP inhibitor boost chemo for tough lung cancer?
- Mapping lung cancer genes to unlock future treatments